RxDoctor Payments Data

Timothy Reed, MD

Family Medicine · Orleans, MANPI 1457320632

Payments from drug & device makers

$1,349in general payments, 2019–2025

Across 75 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$282
  • AstraZeneca$253
  • Pfizer$217
  • Merck$147
  • Scilex Pharmaceuticals Inc.$142
  • Novo Nordisk$107
  • plus $200 from 6 others

What the payments were for

  • Food & beverage$1,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,349 in reported general payments places this provider in the 85th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$114,003
Medicare patients
365
Services billed
1,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$64,806
EliquisApixaban66$56,008
OzempicSemaglutide38$35,879
Tresiba Flextouch U-200Insulin Degludec19$15,490
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,659
MyrbetriqMirabegron22$9,764
Breo ElliptaFluticasone/Vilanterol21$9,705
Atorvastatin Calcium365$5,656
Pantoprazole Sodium175$3,358
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl27$3,340
Tamsulosin Hcl128$2,647
Lisinopril323$2,469
Levothyroxine Sodium160$2,048
Losartan Potassium121$1,909
Amlodipine Besylate272$1,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$282$64,80664 claims
PfizerEliquis$217$56,00866 claims
Novo NordiskOzempic$107$35,87938 claims
GSKTrelegy Ellipta, Breo Ellipta$60$23,36435 claims
Astellas Pharma US IncMyrbetriq$21$9,76422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Orleans

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →